This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes
Sulphonylureas (SU) have received a terrible press in recent years. A series of publications over many years have told us that SUs increase the risk of adverse cardiovascular outcomes in diabetes patients (usually relative to metformin in observational studies),1 analyses from ACCORD and other mega...
| Автори: | , , |
|---|---|
| Формат: | Conference item |
| Опубліковано: |
Association of British Clinical Diabetologists
2016
|